Project Grant R01AI179465
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...
- This $624,902 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to investigate how the HIV accessory protein Vpr induces epigenetic remodeling in myeloid cells, which may contribute to HIV persistence. The research aims to characterize the functional impact of Vpr-directed epigenetic remodeling on the HIV promoter during acute infection and latency reactivation, delineate the mechanisms of...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
- This $823,691 Project Grant award was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to investigate the role of immune checkpoints in the central nervous system (CNS) of people living with HIV (PLWH) and their association with HIV-associated neurocognitive disorder (HAND). The research aims to determine the profiles and biological functions of soluble immune checkpoints (sICPs) in the CNS of PLWH and a simian immunodeficiency...
- This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $232,500 to The Johns Hopkins University to investigate the virologic determinants of very early antiretroviral therapy (ART) responses in infants with in utero HIV-1 infection. The key objectives are to create infectious molecular clones from proviral HIV-1 DNA samples...
- This $564,001 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research on membrane-associated RING CH (MARCH) proteins and their role in restricting HIV-1 infection. MARCH proteins are a family of ubiquitin ligases that regulate membrane receptors and have been shown to restrict HIV-1 and other retroviruses by blocking viral envelope incorporation into budding virions. The research foundation for the State University of New...
- This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to better understand the molecular mechanisms of HIV spread through cell-cell contact across a virological synapse (VS). The $515,282 award will enable Case Western Reserve University (CWRU) to develop a novel flow cytometry assay for quantifying and purifying infected cell-target cell pairs, and leverage...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
- Federal Grant Award Summary: PLANB2CUREHIV Consortium The National Heart, Lung, and Blood Institute (NHLBI) awarded Scripps Research Institute a Project Grant of $3.52 million under the Cardiovascular Diseases Research program (CFDA 93.837) to accelerate pre-clinical development of immunoglobulin heavy chain (IGH)-reprogrammed B cell-based therapies for HIV treatment. The award, initiated September 5, 2025, with completion targeted for June 30, 2030, focuses on developing safe and effective...
- This Project Grant award of $603,338, obligated July 3, 2025, and administered by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), funds research conducted by Yale University through June 30, 2030. The grant supports investigation of HIV-1 (Human Immunodeficiency Virus 1) fusion mechanisms on native membranes using cryo-electron tomography (CryoET) and molecular dynamics (MD) simulations. The research aims to...
VIRAL AND HOST DETERMINANTS OF DONOR-SPECIFIC ANTI-HIV/SIV IMMUNITY MEDIATED BY APOBEC3-ENZYME - PROJECT SUMMARY HUMAN APOBEC3 ENZYMES, PARTICULARLY APOBEC3D, APOBEC3F, APOBEC3G, AND STABLE HAPLOTYPES OF APOBEC3H, CAN INDUCE G>A MUTATIONS IN THE HIV-1 GENOME. OFTEN, THESE MUTATIONS, PARTICULARLY THOSE INFLICTED BY APOBEC3G, WHICH IS A POTENT ANTI-HIV ENZYME, GENERATE STOP CODONS AND LEAD TO HIV-1 INACTIVATION. STUDIES HAVE SHOWN THAT APOBEC3 ENZYMES CAN ALSO INDUCE SUB-LETHAL LEVELS OF MUTATIONS THAT LEAD TO HIV-1 DIVERSIFICATION AND DRUG RESISTANCE. MUTATIONS INFLICTED BY DIFFERENT VARIANTS OF APOBEC3 ENZYMES VARY SUBSTANTIALLY IN TERMS OF BOTH THEIR EXTENT AND SEQUENCE CONTEXT. FOR EXAMPLE, APOBEC3H HAPLOTYPE II OFTEN INDUCES MANY G>A MUTATIONS. BY CONTRAST, APOBEC3H HAPLOTYPE I INDUCES LITTLE OR NO CHANGES IN THE HIV-1 GENOME. ANALYSIS OF ALL REPORTED HIV-1 SEQUENCES FROM ~37,000 PATIENTS SHOW THAT THE EXTENT AND PATTERN OF VIRAL MUTAGENESIS BY APOBEC3 ENZYMES ARE HIGHLY DONOR-SPECIFIC. IT IS HYPOTHESIZED THAT VARIATIONS IN BOTH APOBEC3 AND HIV-1 GENES ARE RESPONSIBLE FOR THE OBSERVED DIFFERENCES IN VIRAL MUTATION PROFILES. THE PRELIMINARY DATA SUGGEST THESE VARIATIONS CREATE A COMPLEX CASCADE OF PATIENT-SPECIFIC INTERACTIONS BETWEEN HIV- 1 AND APOBEC3 ENZYMES UNDERLYING HIV-1 HEALTH DISPARITIES INCLUDING RESPONSES TO ANTIRETROVIRAL TREATMENTS. THIS PROPOSAL AIMS TO INTEGRATE DIVERSE VIRAL AND HOST DATASETS AND USE A COMBINATION OF COMPUTATIONAL AND EXPERIMENTAL TECHNIQUES TO IDENTIFY THE MOLECULAR DETERMINATES OF DIFFERENTIAL VIRAL MUTAGENESIS, AND ELUCIDATE THEIR ROLES IN PATIENT-SPECIFIC RESPONSES TO ANTIRETROVIRAL THERAPIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $822.4k | 5/9/25 | ||
| Not listed | $856.8k | 6/21/24 | ||
| Not listed | $856.8k | 6/21/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
1516401101S | Northwestern University | Project Grant R01AI179465 | $100.0k | 10/30/24 |